CLINICAL TRIALS PROFILE FOR METHICILLIN SODIUM

All Clinical Trials for methicillin sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Johnson & Johnson	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Society for Pediatric Dermatology	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Northwestern University	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT01577524 ↗	The Use of Diluted Povidone Iodine Irrigation in Spine Surgery	Terminated	Attabib, Najmedden, M.D.	Phase 2	2012-01-01	The purpose of the study is to determine whether diluted Povidone Iodine solution used to irrigate surgical wounds during spine surgery decreases the incidence of surgical site infections.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.

Clinical Trial Conditions for methicillin sodium

Condition Name

Condition Name for methicillin sodium
Intervention	Trials
Atopic Dermatitis	1
Atrial Fibrillation	1
Surgical Site Infection	1

Condition MeSH

Condition MeSH for methicillin sodium
Intervention	Trials
Surgical Wound Infection	1
Staphylococcal Infections	1
Eczema	1
Dermatitis, Atopic	1

Clinical Trial Locations for methicillin sodium

Trials by Country

Trials by Country for methicillin sodium
Location	Trials
Brazil	1
Canada	1
United States	1

Trials by US State

Trials by US State for methicillin sodium
Location	Trials
Illinois	1

Clinical Trial Progress for methicillin sodium

Clinical Trial Phase

Clinical Trial Phase for methicillin sodium
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for methicillin sodium
Clinical Trial Phase	Trials
Completed	2
Terminated	1

Clinical Trial Sponsors for methicillin sodium

Sponsor Name

Sponsor Name for methicillin sodium
Sponsor	Trials
Attabib, Najmedden, M.D.	1
Fundação de Amparo à Pesquisa do Estado de São Paulo	1
Federal University of São Paulo	1

Sponsor Type

Sponsor Type for methicillin sodium
Sponsor	Trials
Other	5
Industry	1

Methicillin sodium Market Analysis and Financial Projection

Last updated: April 24, 2026

METHICILLIN SODIUM: Clinical-Trials Status, Market View, and Forward Projection

What is methicillin sodium’s clinical-trials footprint?

Methicillin sodium is an older, narrow-spectrum beta-lactam antibiotic associated with historical hospital use for Staphylococcus infections. The key commercial and clinical constraint is that methicillin itself is effectively obsolete in modern care due to widespread methicillin-resistant Staphylococcus aureus (MRSA) and the dominance of newer anti-MRSA antibiotics.

Clinical-trials update (current state of evidence) A complete, up-to-date clinical-trials update cannot be produced from the information available in the public record accessed here. What is available is the established clinical context: methicillin is not a modern development target and is not listed among active, late-stage, or standard-of-care candidates in contemporary treatment pathways for MRSA. The absence of a current active development pipeline is consistent with the lack of recent regulatory-facing trial activity for methicillin itself (not its analogs).

Implication for investors and R&D

• No credible basis exists for projecting near-term regulatory milestones or new label expansions for methicillin sodium.
• Any “trial update” effort that treats methicillin sodium as an investigational pipeline asset would be inconsistent with the observed position of methicillin in modern antibiotic development.

How is the methicillin sodium market shaped today?

Methicillin sodium is not a scalable commercial category in the current antibiotic market structure because:

• MRSA prevalence drove adoption of next-generation anti-MRSA therapies.
• Modern stewardship and hospital formularies favor agents with better resistance profiles, dosing practicality, and safety/efficacy evidence.

Market structure reality

1. Core demand is legacy and limited: Methicillin sodium is not a mainstream prescribing choice in current hospital antibiotic regimens.
2. Procurement is constrained: Use is typically confined to specific microbiology-driven circumstances, historical stocks, or settings with defined access.
3. Competition is entrenched: The relevant competitive set is dominated by modern MRSA-active beta-lactams and non-beta-lactams (and line extensions), which have replaced methicillin in practice.

What buyers buy instead (directionally)

• New anti-MRSA agents and beta-lactam/beta-lactamase inhibitor strategies have largely displaced methicillin-era beta-lactams for S. aureus coverage.

What market projection is supportable for methicillin sodium?

A forecast can be grounded only in a defined commercial base (installed demand, ongoing procurement, and competitive displacement dynamics). In the absence of a current, measurable revenue engine for methicillin sodium, the only supportable projection is a low-growth or declining trajectory consistent with obsolescence.

Projection (practical range)

• Short term (0 to 2 years): Flat-to-declining demand driven by residual stock and constrained niche use.
• Medium term (3 to 5 years): Declining demand as formularies and supply chains continue to favor newer agents.
• Long term (5+ years): Minimal commercial expansion; any growth would require a specific new clinical or regulatory program, which is not evidenced here.

What are the main strategic constraints for methicillin sodium as an asset?

1. Resistance and standard-of-care displacement
   • MRSA prevalence reduced methicillin’s clinical utility.
2. Development economics
   • Antibiotic trials require large, costly enrollment, stewardship-safe endpoints, and hard-to-replicate comparator landscapes.
3. Regulatory and label relevance
   • Any new label would require modern clinical evidence and would face tight differentiation expectations.

Clinical development outlook: does methicillin sodium have a credible path to renewed trials?

A credible path exists only if a sponsor can establish:

• A modern, unmet clinical need where methicillin still demonstrates measurable clinical utility against contemporary resistance patterns.
• A comparator and endpoint structure that regulators accept for an antibiotic with a highly constrained historical footprint.

No such active pathway is evidenced in the available basis here; therefore, there is no decision-grade path to a trial-driven value unlock in the near term.

---

Key Takeaways

• Methicillin sodium is effectively obsolete in mainstream S. aureus care due to MRSA-driven displacement.
• A decision-grade “clinical trials update” for active or upcoming methicillin sodium studies cannot be established from the available record in this view.
• Market conditions point to flat-to-declining niche demand rather than growth.
• Any meaningful value unlock would require a newly evidenced, regulatory-grade clinical development program, which is not supported by the available evidence context.

---

FAQs

1) Is methicillin sodium currently used to treat MRSA in modern hospitals?
No. Contemporary MRSA management uses newer MRSA-active therapies; methicillin is not a mainstream MRSA option.

2) Are there active late-stage clinical trials for methicillin sodium?
A decision-grade update on active late-stage trials cannot be established from the accessible record in this view.

3) What drives methicillin sodium’s commercial demand today?
Residual niche use shaped by microbiology-driven practices and constrained procurement rather than broad prescribing.

4) What competitive set displaces methicillin sodium?
Modern anti-MRSA antibiotics with stronger resistance handling and evolved dosing and safety profiles.

5) What would need to happen for a meaningful market rebound?
A new, regulator-credible clinical utility demonstration against contemporary resistance and a defensible trial program.

---

References

[1] Centers for Disease Control and Prevention (CDC). (2024). MRSA: About MRSA. https://www.cdc.gov/mrsa/
[2] National Library of Medicine. (n.d.). Methicillin (Drug Information). https://pubchem.ncbi.nlm.nih.gov/ (compound entry varies by registry; accessed via public database landing pages)